Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg; and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg and Apremilast Tablets, 10 mg, 20 mg and 30 mg

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Glenmark Pharmaceuticals and Menarini enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray across numerous markets throughout Europe.

Glenmark Pharmaceuticals receives ANDA tentative approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg

Glenmark Pharmaceuticals receives ANDA tentative approval for Axitinib Tablets,1 mg and 5 mg

Glenmark to divest select Anti-Allergy brands to Dr Reddy’s in Russia, Ukraine, Kazakhstan and Uzbekistan in anticipation of its ‘Ryaltris’ Launch

Glenmark Pharmaceuticals secures its position in the prestigious Dow Jones Sustainability Emerging Markets Index for the third year in a row

Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure

Glenmark Pharmaceuticals receives ANDA approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg

Glenmark’s consolidated revenue increased by 4.88 % to Rs. 29,524.79 mn for Q2 FY 2020-21

Glenmark receives ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg

Glenmark appoints Dipankar Bhattacharjee to its Board of Directors

Glenmark’s consolidated revenue grew by 0.94 % at Rs. 23,447.87 Mn. for Q1 FY 2020-21

Glenmark introduces higher strength (400 mg) of FabiFlu® to reduce pill burden of COVID-19 treatment

Glenmark Announces Top-Line Results From Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19

Glenmark launches world’s first Hypertension Awareness symbol, endorsed by Association of Physicians of India (API) & Hypertension Society of India (HSI)

Glenmark commences 1000 patients Post Marketing Surveillance study with COVID-19 who are administered FabiFlu®

Glenmark’s consolidated revenue rises 7.96% to Rs. 27,674.89 Mn. for Q4 FY2019-20

Glenmark introduces Favipiravir (FabiFlu®) for the treatment of mild to moderate COVID-19 in India

Glenmark becomes the first pharmaceutical company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19

Indian regulator approves Favipiravir for the treatment of mild to moderate COVID-19 in India

Glenmark Pharmaceuticals receives ANDA approval for Fingolimod Capsules, 0.5 mg

Glenmark Pharmaceuticals receives ANDA approval for Chlorzoxazone Tablets USP, 375 mg and 750 mg; Glenmark’s first ANDA approval out of their new U.S. facility

Glenmark to commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India

Glenmark initiates Phase 3 clinical trials on antiviral Favipiravir for COVID-19 patients in India

Glenmark introduces 3-in-1 inhaler therapy for COPD in India, promising reduction in risk of severe attacks and improvement in lung function

Glenmark receives approval from the regulator (DCGI) to conduct Clinical Trials in India on Favipiravir Antiviral tablets for COVID-19 patients